TrialPath
Recruiting

The Impact of Surgical Technique on Circulating Tumor DNA in Stage I-III Non-Small Cell Lung Cancer

NCT05502523 · Thomas Jefferson University
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title
The Impact of Surgical Technique on Circulating Tumor DNA in Early-Stage Non-Small Cell Lung Cancer
About this study
PRIMARY OBJECTIVE: I. To determine the association between sequence of surgical resection and postoperative ctDNA levels at specified time points. SECONDARY OBJECTIVE: I. To determine the associated between sequence of surgical resection and postoperative ctDNA level and clinical oncologic outcomes. II. To assess disease-free survival and the role of circulating tumor DNA in disease recurrence in patients with resectable non-small cell lung cancer. OUTLINE: Patients are randomized to 1 of 2 groups. GROUP I: Patients undergo pulmonary vein first approach surgical procedure on day of surgery. GROUP II: Patients undergo pulmonary artery first approach surgical procedure on day of surgery. After completion of surgery, patients are followed up at day 1, day 7, days 7-28, 4 months, every 6 months for 2 years, then every 6 months for up to 5 years
Eligibility criteria
Inclusion Criteria: * Any patients 18 years of age or older with confirmed or suspected early-stage (stage I-III) NSCLC * Eligible and scheduled for surgical anatomic lung resection (e.g. lobectomy or segmentectomy) as routine clinical care for their disease Exclusion Criteria: * Previous cancer diagnosis within 5 years (except ductal carcinoma in situ \[DCIS\] of the breast, superficial bladder cancer, non-melanoma skin primary, other malignancy that does not require treatment). * Preoperative chemotherapy, immunotherapy, or radiation therapy * Receipt of perioperative blood transfusion
Study design
Enrollment target: 100 participants
Allocation: randomized
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2022-08-31
Estimated completion: 2029-01-01
Last updated: 2026-01-23
Interventions
Procedure: Pulmonary Artery-First Surgical TechniqueProcedure: Biospecimen Collection
Primary outcomes
  • • Circulating tumor deoxyribonucleic acid (ctDNA) status (At postoperative day 2)
  • • Circulating tumor deoxyribonucleic acid (ctDNA) status (At postoperative day 14)
Sponsor
Thomas Jefferson University · other
Contacts & investigators
ContactTyler Grenda, MD · contact · Tyler.grenda@jefferson.edu · 215-955-5562
InvestigatorTyler Grenda, MD · principal_investigator, TJU
All locations (4)
Abington Memorial HospitalRecruiting
Abington, Pennsylvania, United States
Jefferson Health NortheastRecruiting
Philadelphia, Pennsylvania, United States
Thomas Jefferson University HospitalRecruiting
Philadelphia, Pennsylvania, United States
Asplundh Cancer Pavilion at Jefferson HealthRecruiting
Willow Grove, Pennsylvania, United States
The Impact of Surgical Technique on Circulating Tumor DNA in Stage I-III Non-Small Cell Lung Cancer · TrialPath